Title
Selective thromboxane inhibition: a new approach to antiplatelet therapy
UMMS Affiliation
Department of Neurology; Department of Medicine, Division of Cardiovascular Medicine
Date
9-1-1984
Document Type
Article
Subjects
Animals; Cerebrovascular Disorders; Imidazoles; Male; Platelet Aggregation; Swine; Thromboxane B2; Thromboxanes
Disciplines
Medicinal and Pharmaceutical Chemistry | Neurology | Pharmacy and Pharmaceutical Sciences
Abstract
Antiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.
Rights and Permissions
Citation: Stroke. 1984 Sep-Oct;15(5):813-6.
Related Resources
PubMed ID
6474531